ATE236647T1 - Verbesserung der wundheilung mit cm101/gbs-toxin - Google Patents

Verbesserung der wundheilung mit cm101/gbs-toxin

Info

Publication number
ATE236647T1
ATE236647T1 AT98903864T AT98903864T ATE236647T1 AT E236647 T1 ATE236647 T1 AT E236647T1 AT 98903864 T AT98903864 T AT 98903864T AT 98903864 T AT98903864 T AT 98903864T AT E236647 T1 ATE236647 T1 AT E236647T1
Authority
AT
Austria
Prior art keywords
wound healing
gbs toxin
improve wound
keloid
invention includes
Prior art date
Application number
AT98903864T
Other languages
English (en)
Inventor
Carl G Hellerqvist
Michal Neeman
Barbara D Wamil
Rinat Abramovitch
Original Assignee
Univ Vanderbilt
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt, Yeda Res & Dev filed Critical Univ Vanderbilt
Application granted granted Critical
Publication of ATE236647T1 publication Critical patent/ATE236647T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98903864T 1997-01-29 1998-01-29 Verbesserung der wundheilung mit cm101/gbs-toxin ATE236647T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/791,763 US5858991A (en) 1997-01-29 1997-01-29 Facilitation of wound healing with CM101/GBS toxin
PCT/US1998/001853 WO1998032453A1 (en) 1997-01-29 1998-01-29 Facilitation of wound healing with cm101/gbs toxin

Publications (1)

Publication Number Publication Date
ATE236647T1 true ATE236647T1 (de) 2003-04-15

Family

ID=25154717

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98903864T ATE236647T1 (de) 1997-01-29 1998-01-29 Verbesserung der wundheilung mit cm101/gbs-toxin

Country Status (13)

Country Link
US (3) US5858991A (de)
EP (1) EP0973531B1 (de)
JP (1) JP2001509169A (de)
CN (1) CN100389776C (de)
AT (1) ATE236647T1 (de)
AU (1) AU6051898A (de)
DE (1) DE69813200T2 (de)
DK (1) DK0973531T3 (de)
ES (1) ES2196539T3 (de)
HK (1) HK1027755A1 (de)
IL (1) IL131001A0 (de)
PT (1) PT973531E (de)
WO (1) WO1998032453A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
US5981508A (en) * 1997-01-29 1999-11-09 Vanderbilt University Facilitation of repair of neural injury with CM101/GBS toxin
US6803448B1 (en) * 1998-07-22 2004-10-12 Vanderbilt University GBS toxin receptor
US8609614B2 (en) * 1998-07-22 2013-12-17 Vanderbilt University GBS toxin receptor compositions and methods of use
SK10042001A3 (sk) 1999-01-15 2001-12-03 Biogen, Inc. Farmaceutická kompozícia obsahujúca činidlo blokujúce proteín tweak alebo receptor tweak
CN100400100C (zh) * 2000-02-02 2008-07-09 范德比尔特大学 Gbs毒素受体的制药用途
AU5951901A (en) * 2000-05-08 2001-11-20 Biogen Inc Method for promoting neovascularization
US7208151B2 (en) * 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
EP1494713A4 (de) 2002-04-09 2005-12-28 Biogen Idec Inc Verfahren zur behandlung von zuständen im zusammenhang mit tweak
US8017145B2 (en) * 2003-12-22 2011-09-13 Conopco, Inc. Exfoliating personal care wipe article containing an array of projections
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
EP1885388B1 (de) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Behandlung und beurteilung von entzündlichen erkrankungen
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US8877185B2 (en) 2012-05-10 2014-11-04 Stan S. Sastry Managing and treating keloids

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS557014A (en) * 1978-06-29 1980-01-18 Chugai Pharmaceut Co Ltd Antitumor agent and its preparation
US5145676A (en) * 1981-09-08 1992-09-08 The Rockefeller University Method and agents for promoting wound healing
GB8330969D0 (en) * 1983-11-21 1983-12-29 Wellcome Found Promoting healing
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4912093A (en) * 1986-10-01 1990-03-27 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
US5302386A (en) * 1986-04-16 1994-04-12 Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines and methods of manufacture
US4895838A (en) * 1988-03-09 1990-01-23 Trustees Of Boston University Method for provoking angiogenesis by administration of angiogenically active oligosaccharides
US5010062A (en) * 1989-09-25 1991-04-23 Vanderbilt University Therapeutic agent and method of inhibiting vascularization of tumors
US5225331A (en) * 1991-04-25 1993-07-06 National Research Council Of Canada Immunoassay for detecting group b streptococcus
US5160483A (en) * 1991-05-07 1992-11-03 The University Of Tennessee Research Corporation Fragment of TNF-α for promoting wound healing
US5382514A (en) * 1992-03-31 1995-01-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services In vivo angiogenesis assay
DK0666868T4 (da) * 1992-10-28 2006-09-18 Genentech Inc Anvendelse af anti-VEGF-antistoffer til behandling af cancer
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
AU4788396A (en) * 1995-02-16 1996-09-04 Children's Medical Center Corporation Inhibition of angiogenesis using interleukin-12
WO1997041844A1 (en) * 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Combinations of angiostatic compounds
US5811403A (en) * 1996-09-30 1998-09-22 Vanderbilt University Polysaccharide toxin from Group B β-hemolytic Streptococcus (GBS) having improved purity

Also Published As

Publication number Publication date
ES2196539T3 (es) 2003-12-16
IL131001A0 (en) 2001-01-28
AU6051898A (en) 1998-08-18
CN1251998A (zh) 2000-05-03
DK0973531T3 (da) 2003-07-28
HK1027755A1 (en) 2001-01-23
JP2001509169A (ja) 2001-07-10
US6569838B1 (en) 2003-05-27
EP0973531B1 (de) 2003-04-09
PT973531E (pt) 2003-08-29
CN100389776C (zh) 2008-05-28
US20030180331A1 (en) 2003-09-25
EP0973531A1 (de) 2000-01-26
DE69813200D1 (de) 2003-05-15
WO1998032453A1 (en) 1998-07-30
US5858991A (en) 1999-01-12
DE69813200T2 (de) 2004-02-12

Similar Documents

Publication Publication Date Title
ATE236647T1 (de) Verbesserung der wundheilung mit cm101/gbs-toxin
AP1401A (en) Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic- depressive bipolar disorder.
MX9700082A (es) Composicion que consiste de morfina, polipirrolidona y oxido de polialquileno.
DE69636791D1 (de) Derivate von glykopeptidantibiotika
BG100960A (en) Dosage forms for controlled release of azitromycin
PT934061E (pt) Isobutilgaba e seus derivados para o tratamento da dor
EP1147776A3 (de) Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
EP0869801A4 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
GB9521608D0 (en) Pharmaceutical composition
DE69717988D1 (de) Topische verabreichung von premafloxacin zur behandlung von systemischen bakteriellen erkrankungen
DK0445280T3 (da) Terapeutisk middel og fremgangsmåde til inhibering af vaskularisering af tumorer
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
AU1278600A (en) Novel therapeutic application of nicergoline
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
AU1569700A (en) Novel therapeutic application of low molecular weight heparin
TR199801801T2 (xx) Madde k�t�ye kullan�m�n�n tedavisi.
NO984198L (no) FremgangsmÕte for behandling av aggresjon
NO984190L (no) FremgangsmÕte for behandling av insomnia
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
NO981020D0 (no) Transdermalt terapautisk system for silatranforbindelser
ITPR930015V0 (it) cuffia per elettrostimolazione cutanea, vacuum terapia o laser tera- pia.
UA7955A (uk) Спосіб лікування туберкульозу легенів
DE59505934D1 (de) Vitamin b 12-haltige sanddornkonzentrate oder -extrakte
UA29457C2 (uk) Лікувальне покриття
UA8280A (uk) Спосіб лікування псоріазу

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0973531

Country of ref document: EP

REN Ceased due to non-payment of the annual fee